On Invalid Date, 10x Genomics (NASDAQ: TXG) reported Q2 2023 earnings per share (EPS) of -$0.53, up 7.02% year over year. Total 10x Genomics earnings for the quarter were -$62.41 million. In the same quarter last year, 10x Genomics's earnings per share (EPS) was -$0.57.
On Invalid Date, 10x Genomics (NASDAQ: TXG) reported Q2 2023 revenue of $146.82 million up 28.1% year over year. In the same quarter last year, 10x Genomics's revenue was $114.61 million.
What was TXG's revenue growth in the past year?
As of Q3 2023, 10x Genomics's revenue has grown 14.15% year over year. This is 0.58 percentage points higher than the US Health Information Services industry revenue growth rate of 13.57%. 10x Genomics's revenue in the past year totalled $568.41 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.